Clinical Evaluation of Platelet-Rich Plasma Therapy for Vulvar Lichen Sclerosus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600117943

Enrollment

Unknown

Registered

2026-01-30

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vulvar lichen sclerosus

Interventions

Control group:0.05% Chlorhexidine Propionate Cream

Experimental group:PRP therapy

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18-60 years old; 2. At least one clinical symptom and sign of vulvar lichen sclerosus (itching, burning sensation, flushing, edema, epidermal shedding, hypopigmentation, vulvar atrophy, vulvar adhesion, etc.); 3. All patients underwent external genital skin biopsy before treatment, and pathological confirmation showed vulvar lichen sclerosus.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation period; 2. Uncontrolled diabetes and other serious medical diseases that cannot tolerate treatment; 3. Systemic collagen connective tissue disease; 4. Scar constitution; 5. Any one of the four screening criteria is positive; 6. Other skin diseases that are not suitable for platelet rich plasma treatment, such as combined platelet dysfunction syndrome, chronic liver disease, sepsis, and hypoalbuminemia; 7. Local injection, topical or systemic use of glucocorticoids in the treatment area within one month; 8. Oral administration of anticoagulant drugs such as aspirin, warfarin, and rivaroxaban within one week; 9. Smoking; 10. Recent fever history; 11. Severe infections require antibiotic treatment (such as active tuberculosis, sepsis); 12. History of malignant tumors; 13. History of oral and genital herpes; 14. Hemoglobin levels below 10 g/dL or platelet counts below 120x10^9/L; 15. Evaluators of the impact of mental and psychological disorders; 16. Acute or recurrent genital and urinary tract infections of the external genitalia; 17. Epithelial neoplasia or malignant tumors of the external genitalia.

Design outcomes

Primary

Measure	Time frame
vulvar sign score;vulvar symptom score;	—

Secondary

Measure	Time frame
Incidence of side effects;	—

Countries

China

Contacts

Public ContactHu Jun

Peking University First Hospital

hujunjoyce@126.com+86 10 56957099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026